GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » Short Interest

Abivax (LTS:0RA9) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Abivax Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Abivax's Short Interest

For the Biotechnology subindustry, Abivax's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Short Interest distribution charts can be found below:

* The bar in red indicates where Abivax's Short Interest falls into.


;
;

Abivax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » Short Interest
Comparable Companies
XPAR:IVA XPAR:MEDCL XPAR:VLA XPAR:DBV XPAR:ALCLS XPAR:GNFT XPAR:IPH XPAR:NANO XPAR:OSE XPAR:MAAT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ABVX:USA AAVXF:USA ABVX:France 2X1:Germany
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines